Celularity Incorporated
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Celularity Incorporated sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Celularity Incorporated: 14 sponsored US clinical trials, none currently recruiting.
Celularity Incorporated sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peripheral Arterial Disease, with 1 trials.
Top-decile sponsor footprint
Celularity Incorporated ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
5 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (35.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
14 total, page 1 of 1
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
NCT05207722
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
NCT04489420
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
NCT04365101
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
NCT04310592
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
NCT02955550
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
NCT02781467
A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy
NCT02552277
Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
NCT02264288
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
NCT01859117
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
NCT01769755
Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis
NCT01440192
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke
NCT01310114
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis
NCT01261403
PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
NCT01155362
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 5 |
Therapeutic Areas
How the Celularity Incorporated early-phase archive is shaped
14 indexed studies, none listed as recruiting (0% open); 5 completed (36%).
Phase mix: 0 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Peripheral Arterial Disease (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Celularity Incorporated: archived-pipeline peers nationwide
Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Celularity Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 archived trials
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Celularity Incorporated page
14 registered trials is a research-attention snapshot, not an endorsement of Celularity Incorporated or any single study.
- None of Celularity Incorporated's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Peripheral Arterial Disease is the condition Celularity Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peripheral Arterial Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Celularity Incorporated pipeline card: 14 registered trials from official public datasets.Report a data error.